

Phosphorus, Sulfur, and Silicon and the Related Elements

ISSN: 1042-6507 (Print) 1563-5325 (Online) Journal homepage: http://www.tandfonline.com/loi/gpss20

N,N'-(hexane-1,6-diyl)bis(N-((1-aryl/ alkyl-1H-1,2,3-triazol-4-yl)methyl)-4-methyl benzenesulfonamide): Synthesis, antibacterial, antioxidant, and DNA-cleavage activities

Sirassu Narsimha, Kumara Swamy Battula, Lavudya Sudhakar, Nagavelli Vasudeva Reddy & S.K Althaf Hussain

To cite this article: Sirassu Narsimha, Kumara Swamy Battula, Lavudya Sudhakar, Nagavelli Vasudeva Reddy & S.K Althaf Hussain (2016): N,N'-(hexane-1,6-diyl)bis(N-((1-aryl/alkyl-1H-1,2,3triazol-4-yl)methyl)-4-methyl benzenesulfonamide): Synthesis, antibacterial, antioxidant, and DNA-cleavage activities, Phosphorus, Sulfur, and Silicon and the Related Elements

To link to this article: http://dx.doi.org/10.1080/10426507.2016.1146273



Accepted author version posted online: 10 Feb 2016.



🖉 Submit your article to this journal 🕑

Article views: 9



View related articles 🗹



View Crossmark data 🗹

Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=gpss20

Synthesis of 1,2,3-triazol derivatives of 4-methyl benzenesulfonamide

N,N'-(hexane-1,6-diyl)bis(N-((1-aryl/alkyl-1H-1,2,3-triazol-4-yl)methyl)-4-methyl benzenesulfonamide): Synthesis, antibacterial, antioxidant, and DNA-cleavage activities Sirassu Narsimha¹, Kumara Swamy Battula¹, Lavudya Sudhakar¹, Nagavelli Vasudeva Reddy^{1,*}, SK Althaf Hussain²

¹Department of Chemistry, Kakatiya University, Warangal-506009, T. S, India


²Department of Biotechnology, Kakatiya University, Warangal-506 009, T. S, India

*Corresponding author's E-mail: vasujac3@gmail.com

Abstract

Thirteen novel bis-1,2,3-triazole derivatives were synthesized under copper (I)-catalyzed azidealkyne 1, 3-dipolar cycloaddition of N,N'-(hexane-1,6-diyl)bis(4-methyl-N-(prop-2-yn-1yl)benzenesulfonamide) with different aryl azides and evaluated their biological activity. All the newly synthesized compounds were confirmed by ¹H-NMR, IR and ESI-MS spectral studies. The synthesized bis-1, 2, 3-triazoles were evaluated for their antioxidant activity and some of them found to exhibit good to excellent antioxidant activity (IC₅₀: 11.13 ± 1.5 to $98.98 \pm 1.7 \mu$ M) in comparison with standard references Trolox (11.73 \pm 1.5 μ M) and ascorbic acid (3.34 \pm 1.8 μM). The bistriazoles also exhibited excellent to moderate anti-bacterial activity (MIC: 2.253 to 75 ug mL⁻¹ against Bacillus subtilis, Staphylococcus aureus, Escherichia coli and Pseudomonas Streptomycin. N,N'-(hexane-1,6-divl)bis(N-((1-(3,5aeruginosa when compared with dimethylphenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methyl benzenesulfonamide) has completely cleaved DNA at 100 mg mL⁻¹ concentration and the remaining compounds have partially cleaved the DNA.

¹ ACCEPTED MANUSCRIPT



Keywords

Bis-1, 4-disubstituted 1, 2, 3-triazoles, antioxidant, antibacterial, DNA-cleavage activity.

² ACCEPTED MANUSCRIPT

INTRODUCTION

The world population had been suffering from infectious disease due to the multi-drug resistant pathogens against man made antibiotics. Among them, bacterial infections are second most leading death causing diseases after cardiovascular disease in the world, due to their rapid spread, toxicity and resistance towards the existing antibiotic drugs. ¹⁻³ The importance of 1, 2, 3-triazoles in biological systems has attracted great interest due to their medicinal and pharmacological characteristics. Many compounds containing the 1,2,3-triazole moiety have found widespread biological activities, which include antimicrobial, ⁴ anticancer,^{5, 6} antioxidant, ⁷ anti-HIV, ^{8, 9} anti-inflammatory, ¹⁰ antiprotozoal, ¹¹ anticonvulsant, ¹² antihistamine, ¹³ and antitubercular properties. ¹⁴ Such compounds have also been reported as β 3-selective adrenergic receptor agonists, ¹⁵ kinase inhibitors ^{16, 17} and other enzyme inhibitors.^{18,19}

The Cu-catalyzed [3+2] cycloaddition reaction using azide-alkyne was discovered individually by Sharpless and Meldal and led to the fundamental development of the Huisgen thermal reaction and offers a unique approach for the regio selective synthesis of 1,4-disubstituted 1,2,3triazoles. ^{20, 21} The 1,4-disubstituted 1,2,3-triazoles can also be prepared by one-pot three component reaction of substituted halides, sodium azide and terminal alkynes in the presence of a copper catalyst. ²²⁻²⁴ Therefore, in continuation of our research towards the synthesis of biologically potent 1, 2, 3-triazole derivatives, ²⁵⁻²⁸ we report herein, one-pot three component and simple two component synthesis of a small library of N,N'-(hexane-1,6-diyl)bis(4methylbenzenesulfonamide) linked bis1,4-disubstituted 1,2,3-triazole conjugates and their antibacterial, antioxidant and DNA cleavage activities.

RESULTS AND DISCUSSION

³ ACCEPTED MANUSCRIPT

Chemistry

The target bis-1,2,3-triazoles (**5a-h**) and (**6a-e**) were synthesized as outlined in **Scheme S1**. The intermediates **3** and **4** were prepared according to the known reported synthetic route.²⁹ p-toluenesulfonyl chloride (**1**) reacted with hexamethylenediamine(**2**) to form *N*, *N'*- (hexane-1,6-diyl) bis (4-methyl benzene sulfonamide) (**3**). Compound **4** was obtained by the reaction of compound **3** with propargyl bromide and ^tBuOK in DMF at room temperature. The treatment of compound **4** with substituted azides in the presence of a copper (I) catalyst afforded title compounds (**5a-h**). Compound **4** was treated with organic halides, sodium azide and CuI in the presence of THF-H₂O mixture to obtain the desired compounds (**6a-e**) in good to excellent yields.

All the newly synthesized bis triazoles were well characterized by IR, ¹H NMR, elemental analysis and mass (ESI-MS) spectral techniques. The IR spectrum of a representative compound **5a** showed absorption bands in the region 3137-3076 cm⁻¹, which were recognized to = C--H stretching vibrations of the triazole ring. The ¹H NMR spectrum of compound **5a** showed one characteristic singlet at δ 8.01 due to the presence of two triazole protons. A sharp singlet at δ 5.32 confirmed the presence of four protons of two -C*H*₂ groups attached to the triazole ring. The presence of two sharp singlet peaks at δ 3.86 and 2.39, corresponded to the -OC*H*₃ and --C*H*₃ protons attached to the aromatic ring. One triplet signal was observed at δ 3.14, accounted for the protons of the N-C*H*₂- group. Further, all the aromatic protons were observed in the region δ 7.01--7.68. The presence of two multiplets in the region δ 1.34-1.13, confirmed the methylene protons of hexamethylenediamine (-N-CH₂-(CH2)₄-CH₂-N-). The mass spectrum of compound

⁴ ACCEPTED MANUSCRIPT

5a exhibited two signals at m/z 800.2 and m/z 822.4 corresponding to [M+H] and [M+Na], which are in agreement with calculated values.

Antioxidant activity

All the synthesized compounds (**5a-h** and **6a-e**) were screened for *in vitro* antioxidant activity³⁰ and results are presented in Table S 1 (Supplemental Materials). The evaluation of the antioxidant activity revealed that the most of the tested compounds exhibited moderate to strong DPPH radical scavenging ability compared with the positive controls Trolox and ascorbic acid. Among them, the compound bearing 3-(trifluoromethyl)phenyl (**5h**) and 3,5-dichloro phenyl (**5b**) on the triazole ring were found to be more effective and potent DPPH radical scavenging ability as compared with positive control drug Trolax. Remaining compounds have shown good to moderate radical scavenging activity with IC₅₀ values in the range of $28.62 \pm 1.890 - 97.18 \pm 2.051 \mu$ M. From the above results it is obvious that compounds bearing electron attracting groups on the triazole attached phenyl group have found to possess potent radical scavenging ability.

Antibacterial activity

In vitro antibacterial activity was examined using broth dilution method ³¹ and results are presented in Table S 2 (Supplemental Materials). The evaluation of antibacterial data revealed that the most of the tested compounds exhibited moderate to excellent antibacterial activity. Among them, compound **5a** has exhibited excellent activity against *B.Subtilis* (MIC = 2.253 µg mL⁻¹) and S.aureus (MIC = 4.587 µg mL⁻¹). Similarly, compound **5h** showed good activity against *B.Subtilis* (MIC = 6.350 µg mL⁻¹) and *P.aeroginosa* (MIC = 4.687µg mL⁻¹). Compound **6c** also exhibited good activity against *E. coli* (MIC = 2.343 µg mL⁻¹). The remaining

⁵ ACCEPTED MANUSCRIPT

compounds also showed moderate activity against tested microbial strains with MIC ranging from 9.575 to 75 μ g mL⁻¹.

DNA cleavage activity

The DNA cleavage activity of the titled compounds (**5a-h** & **6a-e**) was determined using agarose gel electrophoresis method ^{32, 33} as depicted in Figure S 1. The gel after electrophoresis clearly revealed that, the plasmid pUC18 having three forms of DNA, whereas in case of standard FeSO₄ (10 mg mL⁻¹) complete DNA and partial cleavage was observed. Compared to standard FeSO₄, compound **5g** have completely cleaved the DNA at 100 mg mL⁻¹. The compounds **5b**, **5e** and **6b** showed partial cleavage at 100 mg mL⁻¹.

EXPERIMENTAL

All the solvents and the starting materials were purchased from commercial sources and used without further purification. Column chromatography was performed on silica gel 60--120 mesh. Melting points were determined using a Cintex apparatus. Elemental analysis was measured by means of Perkin Elmer 2400 CHN elemental analyzer. 400 MHz NMR spectrometer was used to acquire ¹H-NMR spectra. Coupling constant (J) values are presented in Hertz and spin multiples are given as s (singlet), d (doublet), t (triplet), and m (multiplet). Mass spectra were recorded by using ESI--MS.

Synthesis of N,N'-(hexane-1,6-diyl)bis(4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide) (4): To a stirred solution of compound 3 (11.8 mmol) in N, N-dimethylformamide (50 mL) was added ^tBuOK (47.16 mmol) at 0°C and the reaction mixture was stirred for 2 h under N₂ atmosphere. After 2 h, propargyl bromide (35.3 mmol) was added drop wise to the reaction mass and stirred at room temperature for 6h. After completion of the reaction by TLC, the reaction

⁶ ACCEPTED MANUSCRIPT

mixture was poured carefully into ice-cold water (100 mL), The solid was filtered off, washed with water and dried to afford N,N'-(hexane-1,6-diyl)bis(4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide). Yield: 68%; mp: 74-76 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, *J* = 8.0 Hz, 4H), 7.43 (d, *J* = 8.2 Hz, 4H), 4.71 (s, 4H, C*H*₂), 3.08 (t, *J* = 4.0 Hz, 4H, N-C*H*₂-CH₂-), 2.41(s, 6H, Ar-CH₃), 2.29 (s, 2H, alkyne-*H*), 1.33 (m, 4H, N-CH₂-C*H*₂-CH₂-),1.15 (m, 4H, N-CH₂-CH₂-CH₂-); ESI-MS m/z: 501.7 [M+H] & 523.4 [M+Na]. Anal. Cal for C₂₆H₃₂N₂O₄S₂: C, 62.37; H, 6.44; N, 5.60; found: C, 62.41; H, 6.47; N, 5.54.

General procedure for 5a-h

To a solution of compound **4** (0.2 g, 0.4 mmol) and arylazide (1.2 mmol) in THF (15mL) was added copper iodide (20 mol-%). The reaction mixture was stirred at room temperature for 8-10 h and the progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with water (15 mL) and the product was extracted with ethyl acetate (2×20 mL). The combined organic layer was dried over anhydrous Na₂SO₄. After filtration, the solvent was evaporated under vacuum and the crude product obtained was purified by column chromatography (hexane/ethyl acetate gradient) to afford the pure desired product.

N,N'-(hexane-1,6-diyl)bis(N-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methyl benzenesulfonamide) (5a): Yield: 68%; mp: 97-99 °C; 8 h; IR (KBr): 3137, 1678, 1594, 1489 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.01(s, 2H, triazole-*H*), 7.68 (d, *J* = 8.0 Hz, 4H, Ar-*H*), 7.61(d, *J* = 8.0, 4H, Ar-*H*), 7.41(d, *J* = 8.2 Hz, 4H, Ar-*H*), 7.01(d, *J* = 8.0, 4H, Ar-*H*), 5.32 (s, 4H, N = N-C*H*₂), 3.86 (s, 6H, -OC*H*₃) 3.14 (t, *J* = 4.4 Hz, 4H, N-C*H*₂-CH₂-), 2.39 (s, 6H, Ar-*CH*₃), 1.32-1.28 (m, 4H, N-CH₂-*CH*₂-CH₂-), 1.18- 1.06 (m, 4H, N-CH₂-*CH*₂-C*H*₂-); ESI-MS

⁷ ACCEPTED MANUSCRIPT

m/z: 800.2 [M+H], 822.4 [M+Na]. Anal. Cal for C₄₀H₄₆N₈O₆S₂: C, 60.13; H, 5.80; N, 14.02; found: C, 60.10; H, 5.86; N, 14.08.

N,N'-(hexane-1,6-diyl)bis(N-((1-(3,5-dichlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-

methyl benzenesulfonamide) (**5b**): Yield: 58%; mp: 112-114 °C; 10 h; IR (KBr): 3152, 1677, 1589, 1492 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.12 (s, 2H, triazole-*H*), 7.82 (s, 2H, Ar-*H*), 7.72 (d, *J* = 8.0 Hz, 4H, Ar-*H*), 7.62 (s, 4H, Ar-*H*), 7.44 (d, *J* = 8.0 Hz, 4H, Ar-*H*), 5.36 (s, 4H, N = N-C*H*₂), 3.17 (t, *J* = 4.0 Hz, 4H, N-C*H*₂-CH₂-), 2.44 (s, 6H, Ar-C*H*₃), 1.42-1.30 (m, 4H, N-CH₂-CH₂-CH₂-CH₂-); ESI-MS m/z: 877.4 [M+H]. Anal. Cal for C₃₈H₃₈Cl₄N₈O₄S₂: C, 52.06; H, 4.37; N, 12.78; found: C, 52.14; H, 4.40; N, 12.80.

N,N'-(hexane-1,6-diyl)bis(N-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methyl

benzenesulfonamide) (**5c**): Yield: 62%; mp: 107-109 °C; 8 h; IR (KBr): 3147, 1680, 1597, 1495 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.08 (s, 2H, triazole-*H*), 7.71 (d, *J* = 8.2 Hz, 4H, Ar-*H*), 7.66 (d, *J* = 7.8 Hz, 4H, Ar-*H*), 7.59-7.43 (m, 8H, Ar-*H*), 5.34 (s, 4H, N-C*H*₂), 3.14 (t, *J* = 4.0 Hz, 4H, N-C*H*₂-CH₂-), 2.42 (s, 6H, Ar-C*H*₃), 1.41-1.29 (m, 4H, N-CH₂-C*H*₂-CH₂-), 1.21- 1.08 (m, 4H, N-CH₂-CH₂-CH₂-CH₂-); ESI-MS m/z: 808.3 [M+H]. 830.7 [M+Na]. Anal. Cal for C₃₈H₄₀Cl₂N₈O₄S₂: C, 56.50; H, 4.99; N, 13.87; found: C, 56.45; H, 4.91; N, 13.79;

N,N'-(hexane-1,6-diyl)bis(N-((1-(4-chloro-3,5-dimethoxyphenyl)-1H-1,2,3-triazol-4-

yl)methyl)-4-methylbenzenesulfonamide) (5d): Yield: 47%; mp: 128-130 °C; 12 h; IR (KBr): 3139, 1689, 1593, 1494 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.10 (s, 2H, triazole-*H*), 7.74 (d, *J* = 8.2 Hz, 4H, Ar-*H*), 7.54 (s, 4H, Ar-*H*), 7.41(d, *J* = 8.2 Hz, 4H, Ar-*H*), 5.33 (s, 4H, N = N-*CH*₂), 3.88 (s, 6H, -OC*H*₃), 3.84 (s, 6H, -OC*H*₃), 3.18 (t, *J* = 4.4 Hz, 4H, N-C*H*₂-CH₂-), 2.41 (s, 6H, Ar-CH₃), 1.42- 1.32 (m, 4H, N-CH₂-*CH*₂-CH₂-), 1.18-1.08 (m, 4H, N-CH₂-*C*H₂-C*H*₂-); ESI-

8 ACCEPTED MANUSCRIPT

MS m/z: 950.7 [M+Na]. Anal. Cal for C₄₂H₄₈Cl₂N₈O₈S₂: C, 54.36; H, 5.21; N, 12.08; found: C, 54.40; H, 5.19; N, 12.13.

N,N'-(hexane-1,6-diyl)bis(N-((1-(4-butylphenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methyl

benzenesulfonamide) (**5e**): Yield: 55%; mp: 83-85 °C; 11h; IR (KBr): 3144, 1667, 1594, 1488 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.99 (s, 2H, triazole-*H*), 7.74-7.66 (m, 8H, Ar-*H*), 7.52-7.38 (m, 8H, Ar-*H*), 5.32 (s, 4H, N = N-C*H*₂), 3.11 (t, *J* = 4.4 Hz, 4H, N-C*H*₂-CH₂-), 2.52-2.41 (m, 10H, Ar-C*H*₃ & Ar-C*H*₂-CH₂-), 1.60-1.52 (m, 4H, Ar-CH₂-C*H*₂-), 1.34-1.24 (m, 8H, N-CH₂-C*H*₃); ESI-MS m/z: 852.2 [M+H]. Anal. Cal for C₄₆H₅₈N₈O₄S₂: C, 64.91; H, 6.87; N, 13.17; found: C, 64.88; H, 6.79; N, 13.24.

N,N'-(hexane-1,6-diyl)bis(4-methyl-N-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl)

benzenesulfonamide) (**5f**): Yield: 57%; mp: 116-118 °C; 11 h; IR (KBr): 3141, 1689, 1594, 1493 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.24 (d, *J* = 7.8 Hz, 4H, Ar-*H*), 8.18 (s, 2H, triazole-*H*), 7.88 (d, *J* = 7.8 Hz, 4H, Ar-*H*), 7.72 (d, *J* = 8.0 Hz, 4H, Ar-*H*), 7.46 (d, *J* = 8.2 Hz, 4H, Ar-*H*), 5.36 (s, 4H, N = N-C*H*₂), 3.18 (t, *J* = 4.4 Hz, 4H, N-C*H*₂-CH₂-), 2.44 (s, 6H, Ar-C*H*₃), 1.42-1.30 (m, 4H, N-CH₂-*C*H₂-CH₂-), 1.22-1.10 (m, 4H, N-CH₂-*C*H₂-); ESI-MS m/z: 852.6 [M+Na]. Anal. Cal for C₃₈H₄₀N₁₀O₈S₂: C, 55.06; H, 4.86; N, 16.90; found: C, 55.12; H, 4.78; N, 16.94.

N,N'-(hexane-1,6-diyl)bis(N-((1-(3,5-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methyl)-4-

methyl benzenesulfonamide) (**5g**): Yield: 66%; mp: 96-98 °C; 10 h; IR (KBr): 3142, 1682, 1592, 1489 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.00 (s, 2H, triazole-*H*), 7.69 (d, *J* = 8.0 Hz, 4H, Ar), 7.43 (d, *J* = 8.2 Hz, 4H, Ar-*H*), 7.35 (s, 4H, Ar), 7.16 (s, 2H, Ar), 5.33 (s, 4H, N = N-

9 ACCEPTED MANUSCRIPT

CH₂), 3.19-3.08 (m, 4H, N-CH₂-CH₂-), 2.40 (s, 6H, Ar-CH₃), 2.38 (s, 12H, Ar-CH₃), 1.46-1.26 (m, 4H, N-CH₂-CH₂-CH₂-), 1.20-1.10 (m, 4H, N-CH₂-CH₂-CH₂-); ESI-MS m/z: 796.4 [M+H]. Anal. Cal for C₄₂H₅₀N₈O₄S₂: C, 63.45; H, 6.34; N, 14.09; found: C, 63.51; H, 6.39; N, 14.14.

N,N'-(hexane-1,6-diyl)bis(4-methyl-N-((1-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-4-yl) methyl)benzenesulfonamide) (5h): Yield: 51%; mp: 124-126 °C; 11 h; IR (KBr): 3161, 1678, 1593, 1496 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.19 (s, 2H, triazole-*H*), 8.03 (s, 2H, Ar), 7.83-7.75 (m, 6H, Ar-*H*), 7.72 (d, *J* = 8.0 Hz, 4H, Ar-*H*), 7.45 (d, *J* = 8.2 Hz, 4H, Ar-*H*), 5.37 (s, 4H, N = N-C*H*₂), 3.18 (t, 4H, N-C*H*₂-CH₂-), 2.44 (s, 6H, Ar-CH₃), 1.42-1.31 (m, 4H, N-CH₂-C*H*₂-CH₂-), 1.28-1.12 (m, 4H, N-CH₂-CH₂-C*H*₂-); ESI-MS m/z: 897.8 [M+Na]. Anal. Cal for C₄₀H₄₀F₆N₈O₄S₂: C, 54.91; H, 4.61; N, 12.81; found: C, 54.88; H, 4.58; N, 12.78.

General procedure for 6a-e

To a solution of compound **4** (0.2 g, 0.4 mmol), organic halide (1.0 mmol) and sodium azide (1.0 mmol) in THF-H₂O mixture (15mL) was added copper iodide (20 mol-%). The reaction mixture was stirred at 60 ° C for 8 h and the progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with water (15 mL) and the product was extracted with ethyl acetate (2×20 mL). The combined organic layer was dried over anhydrous Na₂SO₄. After filtration, the solvent was evaporated under vacuum and the crude product obtained was purified by column chromatography (hexane / ethyl acetate gradient) to afford the pure desired product.

N,N'-(hexane-1,6-diyl)bis(N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-4-methylbenzene

sulfonamide) (**6a**): Yield: 60%; mp: 80-82 °C; 8 h; IR (KBr): 3161, 1671, 1591, 1493 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.79 (s, 2H, triazole-*H*), 7.66 (d, *J* = 8.0 Hz, 4H, Ar-*H*), 7.42 (d, *J* =

¹⁰ ACCEPTED MANUSCRIPT

8.2 Hz, 4H, Ar-H), 7.40-2-7.28 (m, 4H, Ar-H), 7.20-7.00 (m, 6H, Ar-H), 5.30 (s, 4H, N = N-C H_2), 5.20 (s, 4H, Ar- CH_2) 3.09 (t, J = 4.0 Hz, 4H, N- CH_2 - CH_2 -), 2.39 (s, 6H, Ar- CH_3), 1.42-1.28 (m, 4H, N- CH_2 - CH_2 - CH_2 -), 1.22-1.10 (m, 4H, N- CH_2 - CH_2 - CH_2 -); ESI-MS m/z: 768.5 [M+H]. Anal. Cal for C₄₀H₄₆N₈O₄S₂: C, 62.64; H, 6.05; N, 14.61; found: C, 62.57; H, 6.11; N, 14.54

N,N'-(hexane-1,6-diyl)bis(4-methyl-N-((1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl)

benzenesulfonamide) (**6b**): Yield: 58%; mp: 87-89 °C; 8 h; IR (KBr): 3152, 1675, 1594, 1490 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.81 (s, 2H, triazole-*H*), 7.70 (d, *J* = 8.0 Hz, 4H, Ar), 7.42 (d, *J* = 8.2 Hz, 4H, Ar), 7.37-7.27 (m, 4H, Ar), 7.24-7.17 (m, 4H, Ar), 5.31 (s, 4H, N = N-CH₂), 5.22 (s, 4H, Ar-CH₂), 3.11 (t, *J* = 4.4 Hz, 4H, N-C*H*₂-CH₂-), 2.44 (s, 6H, Ar-CH₃), 2.24 (s, 6H, Ar-CH₃), 1.42-1.28 (m, 4H, N-CH₂-CH₂-CH₂-), 1.21-1.09 (m, 4H, N-CH₂-CH₂-CH₂-); ESI-MS m/z: 796.4 [M+H]. Anal. Cal for C₄₂H₅₀N₈O₄S₂ : C, 63.45; H, 6.34; N, 14.09; found: C, 63.41; H, 6.27; N, 14.15.

N,N'-(hexane-1,6-diyl)bis(4-methyl-N-((1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methyl)

benzenesulfonamide) (**6c**): Yield: 55%; mp: 93-95 °C; 8 h; IR (KBr): 3142, 1678, 1590, 1493 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.84 (s, 2H, triazole-*H*), 7.70 (d, *J* = 8.0 Hz, 4H, Ar-*H*), 7.62 (d, *J* = 8.2 Hz, 4H, Ar-*H*), 7.50-7.40 (m, 4H, Ar-*H*), 7.38-7.18 (m, 4H, Ar-*H*), 5.31 (s, 4H, N = N-C*H*₂), 5.22 (s, 4H, Ar-C*H*₂) 3.11 (t, *J* = 4.0 Hz, 4H, N-C*H*₂-CH₂-), 2.42 (s, 6H, Ar-C*H*₃), 1.40-1.30 (m, 4H, N-CH₂-C*H*₂-CH₂-), 1.22-1.10 (m, 4H, N-CH₂-C*H*₂-); ESI-MS m/z: 858.3 [M+H]. Anal. Cal for C₄₀H₄₄N₁₀O₈S₂: C, 56.06; H, 5.18; N, 16.34; found: C, 56.01; H, 5.22; N, 16.28.

¹¹ ACCEPTED MANUSCRIPT

N,N'-(hexane-1,6-diyl)bis(N-((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-4-methyl benzenesulfonamide) (6d): Yield: 62%; mp: 90-92 °C; 8 h; IR (KBr): 3144, 1667, 1592, 1490 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.87 (s, 2H, triazole-*H*), 7.71 (d, *J* = 8.0 Hz, 4H, Ar-*H*), 7.64 (d, *J* = 8.2 Hz, 2H, Ar-*H*), 7.45 (d, *J* = 8.2 Hz, 2H, Ar-*H*), 7.36-7.18 (m, 6H, Ar-*H*), 6.92(d, *J* = 7.8 Hz, 2H, Ar-*H*), 5.33 (s, 4H, N = N-C*H*₂), 5.22 (s, 4H, Ar-C*H*₂), 3.82 (s, 6H, O-CH₃), 3.11 (t, *J* = 4.4 Hz, 4H, N-C*H*₂-CH₂-), 2.43 (s, 6H, Ar-CH₃), 1.42-1.30 (m, 4H, N-CH₂-CH₂-), 1.22-1.10 (m, 4H,N-CH₂-CH₂-CH₂-); ESI-MS m/z: 828.3 [M+H]. Anal. Cal for C₄₂H₅₀N₈O₆S₂: C, 61.00; H, 6.09; N, 13.55; found: C, 61.05; H, 6.16; N, 13.51.

N,N'-(hexane-1,6-diyl)bis(4-methyl-N-((1-(3-methylbenzyl)-1H-1,2,3-triazol-4-yl)methyl) benzenesulfonamide) (6e): Yield: 54%; mp: 86-88 °C; 8 h; IR (KBr): 3131, 1672, 1592, 1494 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.80 (s, 2H, triazole-*H*), 7.69 (d, *J* = 8.0 Hz, 4H, Ar-*H*), 7.40 (d, *J* = 8.2 Hz, 4H, Ar-*H*), 7.38-7.22 (m, 4H, Ar-*H*), 7.20-7.15 (m, 4H, Ar-*H*), 5.33 (s, 4H, N = N-C*H*₂), 5.18 (s, 4H, Ar-C*H*₂), 3.13 (t, *J* = 4.4 Hz, 4H, N-C*H*₂-CH₂-), 2.42 (s, 6H, Ar-C*H*₃), 2.34 (s, 6H, Ar-C*H*₃), 1.41-1.30 (m, 4H, N-CH₂-C*H*₂-CH₂-),1.18-1.08 (m, 4H,N-CH₂-C*H*₂-C*H*₂-); ESI-MS m/z: 796.2 [M+H]. Anal. Cal for C₄₂H₅₀N₈O₄S₂: C, 63.45; H, 6.34; N, 14.09; found: C, 63.50; H, 6.37; N, 14.00.

CONCLUSION

In conclusion, we have synthesized novel bis 1,4-disubstituted 1,2,3-triazoles in good yields, and evaluated their antibacterial, antioxidant and DNA cleavage activities. The compounds **5h** and **5b** showed very good antioxidant activity and the compounds **5a**, **5h** and **6c** showed remarkable antibacterial activity compared to standard drugs. Similarly, compound **5g** showed complete

DNA cleavage at 100 μ g mL⁻¹. These results suggest that the synthesized compounds can be good candidates for future investigations.

¹³ ACCEPTED MANUSCRIPT

AKNOWLEDGEMENTS

The authors Narsimha and Satheesh are thankful to the council of scientific and industrial research - University Grant Commission (CSIR-UGC) New Delhi, for the award of senior research fellowship.

REFERENCES

- [1] Tenover, F. C.; McDonald, L. C. Curr. Opin. Infect. Dis. 2005, 18, 300-305.
- [2] Roberts, M.C. Curr. Drug Targets Infect. Disord. 2004, 4, 207-215.
- [3] Muroi, H.; Nihei, K.; Tsujimoto, K.; Kubo, I. Bioorg. Med. Chem. 2004, 12, 583-587.
- [4] Holla, B. S.; Mahalinga, M.; Karthikeyan, M. S.; Poojary, B.; Akberali, P.M.; Kumari,
 N.S. *Eur. J. Med. Chem.* 2005, 40, 1173-1180.
- [5] Cindy, J. C.; Gregory, M. R.; Janina, M.; Laurent, F. B.; Kasiram, K.; Julia, M.;

Susan, A. C.; Daniela, V.; Claudiu, T. S.; Sally-Ann, P. J. Med. Chem. 2013, 56, 9623-9634.

- [6] Chen, Y.; Lopez-Sanchez, M.; Savoy, D. N.; Billadeau, D. D.; Dow, G. S.;
- Kozikowski, A. P. J. Med. Chem. 2008, 51, 3437-3448.
- [7] Mady, M. F.; Awad, G. E.A.; Jorgensen, K. B. Eur. J. Med. Chem. 2014, 84, 433-443.
- [8] Alvarez, R.; VelAzquez, S.; San-Felix, A.; Aquaro, S.; Clercq, E. De.; Perno, C.-F.;
- Karlsson, A.; Balzarini, J.; Camarasa, M. J. J. Med. Chem. 1994, 37, 4185-4194.
- [9] Velazquez, S.; Alvarez, R.; Perez, C.; Gago, F.; Clercq, E. De.; Balzarini, J.; Camarasa,
- M. J. Antivir. Chem. Chemother. 1998, 9, 481-489.
- [10] Rao, P. S.; Kurumurthy, C.; Veeraswamy, B.; Kumar, G. S.; Poornachandra, Y.;
- Kumar, C. G.; Babu, V. S.; Kotamraju, S.; Narsaiah, B. Eur. J. Med. Chem. 2014, 80,

¹⁴ ACCEPTED MANUSCRIPT

184-191.

- [11] Bakunov, S. A.; Bakunova, S.M.; Wenzler, T.; Ghebru, M.; Werbovetz, K.A.; Brun, R.;Tidwell, R. R. *J. Med. Chem.* 2010, 53, 254-727.
- [12] Kelley, J. L.; Koble, C. S.; Davis, R. G.; McLean, E. W.; Soroko, F. E.; Cooper, B. R. J.*Med. Chem.* 1995, 38, 4131-4134.
- [13] Buckle, D.R.; Rockell, C.J.; Smith, H.; Spicer, B.A. J. Med. Chem. 1986, 29, 2262-2267.
- [14] Patpi, S.R.; Pulipati, L.; Yogeeswari, P.; Sriram, D.; Jain, N.; Sridhar, B.; Murthy, R.;
- [15] Brockunier, L. L.; Parmee, E. R.; Ok, H. O.; Candelore, M. R.; Cascieri, M. A.;
- Colwell, L. F.; Deng, L.; Feeney, W. P.; Forrest, M. J.; Hom, G. J.; MacIntyre, D. E.;
- Tota, L.; Wyvratt, M. J.; Fisher, M. H.; Weber, A. E. *Bioorg. Med. Chem. Lett.* **2000**, 10, 2111-2114.
- [16] Michael, K.; Peter, D.; Dominique, D-S.; Christian, D.; Morten, G. *Org. Biomol. Chem.***2009**, 7, 3421-3429.
- [17] Olesen, P. H.; Sørensen, A. R.; Urso, B.; Kurtzhals, P.; Bowler, A. N.; Ehrbar, U.;
- Hansen, B. F. J. Med. Chem. 2003, 46, 3333-3341.

Anjana, D.T. J. Med. Chem. 2012, 55, 3911-3922.

- [18] Mocharla, V. P.; Colasson, B.; Lee, L. V.; Roeper, S.; Sharpless, B. K.; Wong, C. H.;Kolb, H. C. Angew. Chem. Int. Ed. 2005, 44, 116-120.
- [19] Krasinski, A.; Radic, Z.; Manetsch, R.; Raushel, J.; Taylor, P.; Sharpless, B. K.; Kolb,
 H. C. J. Am. Chem. Soc. 2005, 127, 6686-6692.
- [20] Tornoe, C.W.; Christensen, C.; Meldal, M. J. Org . Chem. 2002, 67, 3057-3064.


¹⁵ ACCEPTED MANUSCRIPT

- [21] Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. Angew. Chem. Int. Ed. 2002,
 41, 2596-2599.
- [22] Sharpless, W.D.; Wu, P.; Hansen, T.V.; Lindberg, J. G. J. Chem. Educ. 2005, 82, 1833-1836.
- [23] Odlo, K.; Hoydahl, E.A.; Hansen, T.V. Tetrahedron Lett. 2007, 48, 2097-2099.
- [24] Kumar, D.; Reddy, V. B.; Kumar, A.; Mandal, D.; Tiwari, R.; Parang, K. *Bioorg. Med.Chem. Lett.* 2011, 21, 449-452.
- [25] Narsimha, S.; Ranjith Kumar, T.; Satheesh Kumar, N.; Yakoob, S.; Vasudeva Reddy, N.*Med. Chem. Res.* 2014, 23, 5321-5327.
- 26] Kumaraswamy. B.; Narsimha, S.; Vasudeva Reddy, N.; Priyanka, B.; Srinivasa Rao. M*J. Serb. Chem. Soc*, **2015**, doi: 10.2298/JSC150818088B.
- [27] Suresh, S.; Narsimha, S.; Kumara Swamy, B.; Alfat Hussain, S.K.; Savitha Jyostna, T.;
- Vasudeva Reddy, N. Eur. J. Chem. 2015, 6, 482-487.
- 28] Ranjith Kumar, T.; Narsimha, S.; Kumara Swamy, B.; Rajendra Chary, V.; Estari, M.;
- Vasudeva Reddy, N. J. Saudi Chem. Soc, 2015, doi: 10.1016/j.jscs.2015.12.001.
- [29] Fischer, J.; Millan, S.; Ritter, H. Beilstein J. Org. Chem. 2013, 9, 2834-2840.
- [30] Mir, Z. G.; Farhan, A.; Anand, K. K.; Insaf, A. Q.; Irfan, A. G. *BMC Complementary Altern. Med.* **2013**, 13, 53.
- [31] National Committee for Clinical Laboratory (NCCL), Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria, which Grows Aerobically, 5th Ed, Approved
- Standard M7- A5, Nat. Comm. Clini. Lab. Standards, Villanova, PA, 2000.
- [32] Biradar, J. S.; Sasidhar, B. S.; Parveen, R. Eur. J. Med. Chem. 2010, 45, 4074-4078.

¹⁶ ACCEPTED MANUSCRIPT

[33] Sasidhar, B. S.; Birdar, J. S. Med. Chem. Res. 2013, 22, 3518-3526.

¹⁷ ACCEPTED MANUSCRIPT



Scheme 1: Synthetic route: i) THF / 10% NaOH; ii) propargyl bromide/ ^tBuOK, DMF, rt, 12 h;

iii) ArN₃/ CuI, THF, rt, 8-12 h; iv) Ar¹CH₂-Br / NaN₃, THF-H₂O, 60 °C, 8 h.

¹⁸ ACCEPTED MANUSCRIPT